Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

Next Previous
Trial Profile

A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary) ; Methotrexate; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FEATURE
  • Sponsors Genentech; Roche

Most Recent Events

  • 21 May 2010 Status changed from suspended to discontinued.
  • 20 May 2010 According to a Roche/Biogen Idec media release, the ocrelizumab rheumatoid arthritis clinical development programme (including this and the SCRIPT, FILM and STAGE trials) has been discontinued due to an unfavourable overall benefit to risk profile.
  • 08 Mar 2010 Treatment of patients has been suspended after recommendation from the Ocrelizumab RA and Lupus DSMB based on an assessment of this and the SCRIPT, FILM, STAGE, and two lupus trials (BELONG and BEGIN), as reported in a Roche/Biogen Idec media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top